Cancer News

Inherited pancreatic cancer risk mutation identified (08/15/2019)

Scientists have found a rare, inherited gene mutation that raises the risk of pancreatic cancer and other malignancies In the future, individuals with a strong family history of pancreatic cancer could be tested to determine if they carry the mutation. Scientists studying a highly cancer-prone family have identified a rare, inherited gene mutation that dramatically... Continue Reading

CD40 Combination Therapy Can Shrink Pancreatic Tumors (04/04/2019)

A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients – 20 out of 24 as of an interim analysis of the phase 1b trial data. The early findings provide hope that this strategy involving a CD40 antibody, a checkpoint inhibitor, and standard-of-care chemotherapy could... Continue Reading

Lynparza Delays Progression of BRCA-mutated Metastatic Pancreatic Cancer (03/18/2019)

Lynparza (olaparib) improves progression-free survival (PFS) when used to treat BRCA-mutated pancreatic cancer and appears to represent a new treatment option for this hard to treat cancer. (1-4) About BRCA Mutated Pancreatic Cancer Pancreatic cancer has the worst survival rate of the most common cancers and less than seven percent of patients survive more than... Continue Reading

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer (02/28/2019)

Results from the trial showed a significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) for the treatment of BRCA-mutated pancreatic cancer. POLO is a randomised, double-blinded, placebo-controlled trial exploring the efficacy of Lynparza tablets as 1st-line maintenance monotherapy in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose... Continue Reading

Laurie MacCaskill Partners with CancerConnect (10/19/2018)

KETCHUM – LOS ANGELES: Laurie MacCaskill, a 12-year survivor of pancreatic cancer and former chair of the Pancreatic Cancer Action Network has announced a newly established partnership with Cancer Connect to support pancreatic cancer patients with information, support and inspiration. Cancer Connect, a national organization provides support and information to more than 1 million patients …

Continue reading "Laurie MacCaskill Partners with CancerConnect"

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer (06/19/2018)

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of …

Continue reading "mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer"

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study (04/18/2018)

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people …

Continue reading "First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study"

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer (03/05/2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase 2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab …

Continue reading "Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer"

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer (02/28/2018)

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology in …

Continue reading "Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer"

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising (07/11/2017)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking place June 28 through July 1, 2017 in Barcelona, Spain. AM0010 is being evaluated in an ongoing Phase 1/1b clinical trial that has enrolled 352 advanced cancer patients and in a …

Continue reading "Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising"